To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.
Expert Interview Hematologic Malignancies
Recent Advances in Multiple Myeloma
An Expert Interview with Shaji K Kumar
Mayo Clinic, Rochester, Minnesota, US
O ncology & Hematology Review (US) are delighted to introduce our new Editor-in-Chief,
Shaji K Kumar, consultant in the Division of Hematology at Mayo Clinic, and Professor
of Medicine in the College of Medicine, Mayo Clinic, Rochester, Minnesota, US. In a
recent interview, Dr Kumar discussed the latest advances in multiple myeloma, one of his major
Keywords Multiple myeloma, disease
Disclosure: Shaji K Kumar has nothing to
disclose in relation to this article. This is an expert
interview, and as such has not undergone the
journal's standard peer review process.
Acknowledgments: Medical writing assistance was
provided by Katrina Mountfort, Freelance Medical
Writer, supported by Touch Medical Media.
Authorship: All named authors meet the International
Committee of Medical Journal Editors (ICMJE) criteria
for authorship of this manuscript, take responsibility
for the integrity of the work as a whole, and have
given final approval to the version to be published.
Open Access: This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any noncommercial use, distribution,
adaptation, and reproduction provided the original
author(s) and source are given appropriate credit.
Received: February 27, 2017
Published Online: April 14, 2017
Citation: Oncology & Hematology Review,
2017;13(1):13–4 Corresponding Author: Shaji K Kumar, MD,
Professor of Medicine, Division of Hematology,
Mayo Clinic, 200 First Street SW, Rochester,
MN 55905, US. E: [email protected]
TOU CH MED ICA L MEDIA
Oncology and Hematology Review (US) would like to welcome our new Editor-in-Chief, Shaji K Kumar,
MD. Dr Kumar is a consultant in the Division of Hematology at Mayo Clinic, and Professor of Medicine in
the College of Medicine, Mayo Clinic, Rochester, Minnesota, US. He is currently the chair of the NCCN
panel on multiple myeloma and is the co-chair of the NCI multiple myeloma steering committee.
A significant component of Dr Kumar’s research efforts are directed toward studying novel
treatment approaches in myeloma through well-designed clinical trials. He is principal investigator
on multiple phase I, II, and III trials for plasma cell malignancies, which include a combination of
Mayo investigator-initiated trials, industry-sponsored trials, and cooperative group trials. From
a translational research standpoint, his laboratory has focused on development of new agents
for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar
receives ongoing support for research from the National Institutes of Health and the National
Cancer Institute. He is a member of several professional societies, including the American Society
of Hematology, American Society of Clinical Oncology, American Association for Clinical Research,
American Society for Blood and Marrow Transplantation, American Medical Association, Association
of Physicians of India, and the European Hematology Association. His work has appeared in peer
reviewed journals such as Lancet Oncology, Journal of Clinical Oncology, Blood Cancer Journal,
Leukemia, American Journal of Hematology, Mayo Clinic Proceedings, Blood, and European Journal
of Hematology. He received his medical degree from the All India Institute of Medical Sciences, New
Delhi, India. He completed an internship there, followed by a clinical residency in internal medicine
and a senior residency in medical oncology. Dr Kumar subsequently completed a residency in
internal medicine and a fellowship in hematology/oncology at Mayo Graduate School of Medicine.
He then spent time as a research associate and Mayo Foundation Scholar in multiple myeloma at
Dana-Farber Cancer Institute-Harvard Cancer Center.